Levels of RNA A → I editing observed among AML genotypes vary, with patients carrying CEBPA and NPM1 mutations having lower levels in contrast to patients carrying mutated chromatin regulators and TP53. The gene discussed is CEBPA; the disease is acute myeloid leukemia.